Phase II study of a combination of elliptinium and vinblastine in metastatic breast cancer

Abstract

Thirty nine patients with metastatic breast cancer, all previously treated with chemotherapy including anthracycline, were given Elliptinium acetate (80 mg/m2/day) and a continuous infusion of Vinblastine (2 mg/m2/day) for 3 consecutive days every 4 weeks. Twenty nine patients had measurable metastatic disease. Nine (31%) achieved a partial response. No complete response was observed. Median duration of response was 6 months. The response rate was dependent on the number of metastatic sites and independent of the number of previous chemotherapy regimes. Side effects were dry mouth (27 patients), vomiting (9), neutropenia (3 patients with grade IV, 2 with grade III), muscle cramps (5) and thrombosis (3). Xerostomia and vomiting contributed to weight loss and fatigue (8 patients). We conclude that Elliptinium-Vinblastine combination has moderate activity as second line treatment in metastatic breast cancer. This combination causes xerostomia and fatigue with moderate myelosuppression.

Evaluation of Interactions of Selected Olivacine Derivatives with DNA and Topoisomerase II

“…One of the newly synthesized ellipticine derivatives was elliptinium. This compound was used in France for the treatment of metastatic breast cancer, but after several years of use, it was withdrawn due to adverse side effects (severe xerostomia and vomiting, hemolysis, phlebitis, fatigue, muscle cramps) [10]. The other interesting olivacine derivative was S16020, which reached phase II clinical investigations [11][12][13].…”